clinical trial · NCT07089992
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
SarcomaPembrolizumab
brief summary
The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma. The researchers will also study how the immune system responds to the study treatment. Pembrolizumab is a type of drug called a PD-1 inhibitor. It is designed to block a protein called programmed cell death protein 1 (PD-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.
started
Dec 4, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Dec 16, 2025
official title
URSa-1: A Minibasket Study of Pembrolizumab in Ultra-Rare Sarcomas
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol